BEIJING: A total of seven Chinese-made Covid-19 vaccines have entered Phase 3 clinical trials, according to an official with the Ministry of Science and Technology (MOST).
China now has 16 self-developed Covid-19 vaccines undergoing clinical trials, said Wu Yuanbin, director-general of science and technology for social development with MOST, at a recent conference on hematology.
An inactivated vaccine developed by Beijing Biological Products Institute Co Ltd under the China National Biotec Group, affiliated with Sinopharm, was last month the first to receive conditional market approval from the National Medical Products Administration.
The interim results of its Phase 3 clinical trials showed 79.34% efficacy against Covid-19.
The mainland on Saturday reported 92 newly confirmed cases, including 73 locally transmitted and 19 arriving from outside the mainland, the National Health Commission said yesterday.
Of the locally transmitted cases, 63 were reported in Jilin, nine in Heilongjiang, and one in Hebei, the commission said in its daily report.
No suspected case was reported.
No deaths related to the disease were reported on Saturday, said the commission. By the end of Saturday, the mainland had reported 4,708 imported cases in total.
Among them, 4,399 had been discharged from hospitals and 309 remained hospitalised.
No deaths had been reported among the imported cases. — China Daily/ANN
